Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates

Michiyo Deushi, Mizuko Osaka, Kaku Nakano, Kyoichi Osada, Kensuke Egashira, Masayuki Yoshida

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Oxidized cholesterol (oxysterols) plays an important and multifaceted role in lipid metabolism. Here we examined whether dietary oxysterols accelerate hepatic lipid accumulation and inflammation in nonhuman primates. We also examined the effect of the Niemann–Pick C1-like1 inhibitor, ezetimibe (Ez). Macaca fascicularis (5-year-old males) were fed either regular cholesterol + high-fat diet (control-HFD) or oxysterols + high-fat diet (ox-HFD; with 0.015% of oxysterols cholesterol) for 24 weeks. Compared with control-HFD, ox-HFD did not affect plasma lipid levels, but it did affect hepatic lipid levels [total cholesterol, 40.9 mg·g−1 (ox-HFD) versus 3.2 (control-HFD) mg·g−1; triglycerides, 28.0 (ox-HFD) versus 5.7 (control-HFD) mg·g−1]. Ox-HFD increased lipid accumulation as well as recruitment of inflammatory cells when compared to control-HFD. We then examined the effects of Ez, 0.2 mg·kg−1·day−1 for 12 weeks. In addition to a significant reduction in dyslipidemia, Ez alleviated biochemical and pathological aspects of steatosis. Dietary oxysterols aggravate steatosis in nonhuman primates. Treatment with Ez may be a novel therapeutic approach to NAFLD by alleviating dyslipidemia.

Original languageEnglish
Pages (from-to)1008-1015
Number of pages8
JournalFEBS Open Bio
Volume6
Issue number10
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Primates
Cholesterol
Liver
Lipids
High Fat Diet
Nutrition
Dyslipidemias
Fats
Macaca fascicularis
Lipid Metabolism
Triglycerides
Oxysterols
Ezetimibe
Inflammation
Plasmas
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates. / Deushi, Michiyo; Osaka, Mizuko; Nakano, Kaku; Osada, Kyoichi; Egashira, Kensuke; Yoshida, Masayuki.

In: FEBS Open Bio, Vol. 6, No. 10, 01.10.2016, p. 1008-1015.

Research output: Contribution to journalArticle

Deushi, Michiyo ; Osaka, Mizuko ; Nakano, Kaku ; Osada, Kyoichi ; Egashira, Kensuke ; Yoshida, Masayuki. / Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates. In: FEBS Open Bio. 2016 ; Vol. 6, No. 10. pp. 1008-1015.
@article{dbbd02d065c944f6b851290eb55f75bd,
title = "Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates",
abstract = "Oxidized cholesterol (oxysterols) plays an important and multifaceted role in lipid metabolism. Here we examined whether dietary oxysterols accelerate hepatic lipid accumulation and inflammation in nonhuman primates. We also examined the effect of the Niemann–Pick C1-like1 inhibitor, ezetimibe (Ez). Macaca fascicularis (5-year-old males) were fed either regular cholesterol + high-fat diet (control-HFD) or oxysterols + high-fat diet (ox-HFD; with 0.015{\%} of oxysterols cholesterol) for 24 weeks. Compared with control-HFD, ox-HFD did not affect plasma lipid levels, but it did affect hepatic lipid levels [total cholesterol, 40.9 mg·g−1 (ox-HFD) versus 3.2 (control-HFD) mg·g−1; triglycerides, 28.0 (ox-HFD) versus 5.7 (control-HFD) mg·g−1]. Ox-HFD increased lipid accumulation as well as recruitment of inflammatory cells when compared to control-HFD. We then examined the effects of Ez, 0.2 mg·kg−1·day−1 for 12 weeks. In addition to a significant reduction in dyslipidemia, Ez alleviated biochemical and pathological aspects of steatosis. Dietary oxysterols aggravate steatosis in nonhuman primates. Treatment with Ez may be a novel therapeutic approach to NAFLD by alleviating dyslipidemia.",
author = "Michiyo Deushi and Mizuko Osaka and Kaku Nakano and Kyoichi Osada and Kensuke Egashira and Masayuki Yoshida",
year = "2016",
month = "10",
day = "1",
doi = "10.1002/2211-5463.12107",
language = "English",
volume = "6",
pages = "1008--1015",
journal = "FEBS Open Bio",
issn = "2211-5463",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Ezetimibe reduced hepatic steatosis induced by dietary oxysterols in nonhuman primates

AU - Deushi, Michiyo

AU - Osaka, Mizuko

AU - Nakano, Kaku

AU - Osada, Kyoichi

AU - Egashira, Kensuke

AU - Yoshida, Masayuki

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Oxidized cholesterol (oxysterols) plays an important and multifaceted role in lipid metabolism. Here we examined whether dietary oxysterols accelerate hepatic lipid accumulation and inflammation in nonhuman primates. We also examined the effect of the Niemann–Pick C1-like1 inhibitor, ezetimibe (Ez). Macaca fascicularis (5-year-old males) were fed either regular cholesterol + high-fat diet (control-HFD) or oxysterols + high-fat diet (ox-HFD; with 0.015% of oxysterols cholesterol) for 24 weeks. Compared with control-HFD, ox-HFD did not affect plasma lipid levels, but it did affect hepatic lipid levels [total cholesterol, 40.9 mg·g−1 (ox-HFD) versus 3.2 (control-HFD) mg·g−1; triglycerides, 28.0 (ox-HFD) versus 5.7 (control-HFD) mg·g−1]. Ox-HFD increased lipid accumulation as well as recruitment of inflammatory cells when compared to control-HFD. We then examined the effects of Ez, 0.2 mg·kg−1·day−1 for 12 weeks. In addition to a significant reduction in dyslipidemia, Ez alleviated biochemical and pathological aspects of steatosis. Dietary oxysterols aggravate steatosis in nonhuman primates. Treatment with Ez may be a novel therapeutic approach to NAFLD by alleviating dyslipidemia.

AB - Oxidized cholesterol (oxysterols) plays an important and multifaceted role in lipid metabolism. Here we examined whether dietary oxysterols accelerate hepatic lipid accumulation and inflammation in nonhuman primates. We also examined the effect of the Niemann–Pick C1-like1 inhibitor, ezetimibe (Ez). Macaca fascicularis (5-year-old males) were fed either regular cholesterol + high-fat diet (control-HFD) or oxysterols + high-fat diet (ox-HFD; with 0.015% of oxysterols cholesterol) for 24 weeks. Compared with control-HFD, ox-HFD did not affect plasma lipid levels, but it did affect hepatic lipid levels [total cholesterol, 40.9 mg·g−1 (ox-HFD) versus 3.2 (control-HFD) mg·g−1; triglycerides, 28.0 (ox-HFD) versus 5.7 (control-HFD) mg·g−1]. Ox-HFD increased lipid accumulation as well as recruitment of inflammatory cells when compared to control-HFD. We then examined the effects of Ez, 0.2 mg·kg−1·day−1 for 12 weeks. In addition to a significant reduction in dyslipidemia, Ez alleviated biochemical and pathological aspects of steatosis. Dietary oxysterols aggravate steatosis in nonhuman primates. Treatment with Ez may be a novel therapeutic approach to NAFLD by alleviating dyslipidemia.

UR - http://www.scopus.com/inward/record.url?scp=84988384559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988384559&partnerID=8YFLogxK

U2 - 10.1002/2211-5463.12107

DO - 10.1002/2211-5463.12107

M3 - Article

AN - SCOPUS:84988384559

VL - 6

SP - 1008

EP - 1015

JO - FEBS Open Bio

JF - FEBS Open Bio

SN - 2211-5463

IS - 10

ER -